Is Vaxart Inc (VXRT) overvalued? · rev $28.7M
Vaxart Inc (VXRT) is a biotechnology company listed on US.
This page asks whether Vaxart Inc (VXRT) looks expensive on cached numbers — not a short thesis.
Latest reported VXRT revenue for 2024-12-31 was $28.7M. Net income was -$66.9M. Revenue was up 288.9% from 2023-12-31 to 2024-12-31. VXRT currently screens at market cap $73.0M.
VXRT currently screens at market cap $73.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VXRT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VXRT stock page for the full model, not this heading.
Not investment advice.